Executive Summary: The Evolving Landscape of Incretin Therapies
In the rapidly advancing field of metabolic medicine, the shift from a glucose-centric approach to a cardio-protective strategy has redefined the management of type 2 diabetes (T2D). While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as dulaglutide and semaglutide have established themselves as pillars of cardiovascular risk reduction, the emergence of dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists—specifically tirzepatide—has raised critical questions regarding comparative superiority. A landmark study by Ostrominski et al., published in Diabetes Care, provides a rigorous evaluation of these therapies using target-trial emulation. The findings suggest that tirzepatide offers a significant advantage over dulaglutide in reducing major adverse cardiovascular events (MACE) and all-cause mortality, while demonstrating comparable efficacy to semaglutide in a high-risk population with atherosclerotic cardiovascular disease (ASCVD).
Key Highlights
1. Tirzepatide was associated with a 20% lower risk of modified MACE compared to dulaglutide (HR 0.80). 2. The benefit over dulaglutide was largely driven by a 40% reduction in all-cause mortality (HR 0.60). 3. Cardiovascular outcomes between tirzepatide and semaglutide initiators were similar, with no statistically significant difference in MACE. 4. Post hoc analysis revealed a potential secondary benefit of tirzepatide in reducing pneumonia-related hospitalizations compared to dulaglutide.
Background: Addressing the High Burden of ASCVD in Type 2 Diabetes
Patients with T2D face a significantly elevated risk of cardiovascular complications, which remains the leading cause of morbidity and mortality in this population. For years, the standard of care for patients with T2D and established ASCVD has included GLP-1 RAs, supported by robust data from cardiovascular outcomes trials (CVOTs) like LEADER and REWIND. However, tirzepatide, a first-in-class dual agonist, has demonstrated superior glycemic control and weight loss in the SURPASS clinical trial program. Despite these metabolic gains, direct head-to-head cardiovascular outcome data from randomized controlled trials (RCTs) are still pending (notably the SURPASS-CVOT). In the interim, target-trial emulation—a sophisticated epidemiological method designed to mimic the design of an RCT using real-world data—serves as a crucial tool for clinicians and policy makers to understand the comparative effectiveness of these potent agents.
Study Design: The Rigor of Target-Trial Emulation
The study utilized data from commercially insured adults in the United States between June 2022 and December 2024. The investigators focused on a high-risk cohort: adults with T2D and documented ASCVD who were initiating subcutaneous tirzepatide, dulaglutide, or semaglutide. To minimize selection bias and confounding—common pitfalls in observational research—the researchers employed propensity score (PS) matching. This ensured that compared groups were balanced across a wide array of clinical and demographic variables, including age, sex, baseline HbA1c, comorbidities, and concomitant medication use.
Endpoints and Methodology
The primary outcome was ‘modified MACE,’ defined as a composite of nonfatal myocardial infarction (MI), nonfatal stroke, and all-cause death. The study was structured into two distinct emulations: 1. Tirzepatide vs. Dulaglutide: 9,233 pairs of initiators were matched. 2. Tirzepatide vs. Semaglutide: 25,266 pairs of initiators were matched. Outcomes were analyzed using incidence rates (IRs) per 1,000 person-years and hazard ratios (HRs) with 95% confidence intervals (CIs).
Comparative Effectiveness: Tirzepatide vs. Dulaglutide
The results of the first emulation provided strong evidence for the clinical superiority of tirzepatide over dulaglutide. Tirzepatide initiators experienced a significantly lower rate of modified MACE, with an incidence rate of 31.3 per 1,000 person-years compared to 39.4 for dulaglutide initiators. This translated to a hazard ratio of 0.80 (95% CI 0.65-0.99), indicating a 20% relative risk reduction.
The Mortality Benefit
Perhaps the most striking finding was the impact on mortality. Tirzepatide was associated with a 40% reduction in all-cause mortality compared to dulaglutide (HR 0.60; 95% CI 0.43-0.83). While the composite MACE endpoint was reached, the individual components of nonfatal MI and stroke did not reach statistical significance on their own, suggesting that the overall MACE benefit was heavily influenced by the survival advantage.
Direct Comparison: Tirzepatide vs. Semaglutide
In the second emulation, which compared tirzepatide to semaglutide, the results were more balanced. The incidence of modified MACE was nearly identical between the two groups: 23.7 per 1,000 person-years for tirzepatide versus 23.2 for semaglutide. The hazard ratio was 1.03 (95% CI 0.90-1.17), signaling no significant difference in cardiovascular protection between these two highly potent agents in routine clinical care. These findings suggest that for the prevention of MACE in patients with T2D and ASCVD, tirzepatide and semaglutide may be considered roughly equivalent based on current real-world evidence.
Mechanistic Insights and Post Hoc Observations
The superiority of tirzepatide over dulaglutide, but not semaglutide, may be attributed to several factors. First, tirzepatide and semaglutide generally produce more profound reductions in HbA1c and body weight compared to dulaglutide. The dual agonism of GIP and GLP-1 receptors may also provide synergistic effects on endothelial function, systemic inflammation, and lipid metabolism that exceed those of older GLP-1 RAs.Interestingly, a post hoc analysis found that tirzepatide was associated with lower rates of pneumonia-related hospitalization compared with dulaglutide. While the exact biological mechanism remains speculative, it may relate to improved overall metabolic health, reduced systemic inflammation, or weight-loss-mediated improvements in respiratory mechanics.
Clinical Implications and Expert Commentary
This study has significant implications for clinical practice guidelines. For patients with T2D and ASCVD, the choice of an incretin-based therapy is no longer just about glycemic control. The data suggest that tirzepatide and semaglutide are the preferred agents for cardiovascular risk reduction. Expert commentators note that while target-trial emulations are robust, they cannot fully replace RCTs. The medical community is eagerly awaiting the results of the SURPASS-CVOT, which is specifically designed to compare tirzepatide against dulaglutide in a controlled setting. However, the Ostrominski study provides high-quality ‘bridge’ evidence that tirzepatide is a formidable option for secondary prevention.
Study Limitations
The authors acknowledge certain limitations, including the reliance on administrative claims data, which may lack some clinical nuances like exact duration of diabetes or specific lifestyle factors. Additionally, the follow-up period reflects the relatively recent market entry of tirzepatide, and longer-term data will be essential to confirm these findings.
Conclusion
Among adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide initiators experienced a lower risk of major adverse cardiovascular events and all-cause mortality when compared with those starting dulaglutide. In contrast, cardiovascular outcomes appeared similar between tirzepatide and semaglutide. These results support the use of tirzepatide as a high-efficacy tool for both metabolic and cardiovascular management, reinforcing the importance of drug selection in optimizing outcomes for high-risk patients.
References
1. Ostrominski JW, Ortega-Montiel J, Wexler DJ, et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. Diabetes Care. 2026. PMID: 41778928. 2. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 3. Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetologia.
